Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C; Swiss Group for Clinical Cancer Research SAKK.

Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2.

2.

Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study.

Ham JC, van Herpen CML, Driessen CML, van der Graaf WTA, Husson O.

Oral Oncol. 2019 Sep;96:105-112. doi: 10.1016/j.oraloncology.2019.07.014. Epub 2019 Jul 17.

3.

Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma.

Joerger M, Güller U, Bastian S, Driessen C, von Moos R.

J Gastrointest Oncol. 2019 Apr;10(2):373-378. doi: 10.21037/jgo.2018.11.04.

4.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.

JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402. Erratum in: JAMA Oncol. 2019 Jul 1;5(7):1070.

5.

Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).

Driessen CM, Ham JC, Te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, van Herpen CM.

Cancers (Basel). 2019 Apr 17;11(4). pii: E551. doi: 10.3390/cancers11040551.

6.

Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.

Ham JC, Driessen CM, Hendriks MP, Fiets E, Kreike B, Hoeben A, Slingerland M, van Opstal CC, Kullberg BJ, Jonker MA, Adang EM, Kaanders JH, van der Graaf WT, van Herpen CM.

Eur J Cancer. 2019 May;113:32-40. doi: 10.1016/j.ejca.2019.02.013. Epub 2019 Apr 6.

PMID:
30965213
7.

Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.

Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou RC, Chatterjee M.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4.

PMID:
30954557
8.

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Samaras P, Bargetzi M, Betticher DC, Driessen C, Duchosal MA, Heim D, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2019 Apr 3;149:w20031. doi: 10.4414/smw.2019.20031. eCollection 2019 Mar 25.

9.

Management of cardiovascular risk in patients with multiple myeloma.

Plummer C, Driessen C, Szabo Z, Mateos MV.

Blood Cancer J. 2019 Feb 26;9(3):26. doi: 10.1038/s41408-019-0183-y. Review.

10.

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.

Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira RB, Castellano RK, Law BK, Driessen C.

Haematologica. 2019 Sep;104(9):e415-e419. doi: 10.3324/haematol.2018.207704. Epub 2019 Feb 21. No abstract available.

11.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.

12.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

PMID:
30725503
13.

Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.

Hoemme A, Barth H, Haschke M, Krähenbühl S, Strasser F, Lehner C, von Kameke A, Wälti T, Thürlimann B, Früh M, Driessen C, Joerger M.

Cancer Chemother Pharmacol. 2019 Apr;83(4):763-774. doi: 10.1007/s00280-019-03783-9. Epub 2019 Jan 25.

PMID:
30684020
14.

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.

Xin BT, Huber EM, de Bruin G, Heinemeyer W, Maurits E, Espinal C, Du Y, Janssens M, Weyburne ES, Kisselev AF, Florea BI, Driessen C, van der Marel GA, Groll M, Overkleeft HS.

J Med Chem. 2019 Feb 14;62(3):1626-1642. doi: 10.1021/acs.jmedchem.8b01884. Epub 2019 Feb 5.

15.

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.

Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin BT, de Bruin G, Maurits E, Overkleeft HS, Driessen C.

Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3. doi: 10.1016/j.chembiol.2018.11.007. Epub 2019 Jan 3.

PMID:
30612952
16.

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.

Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.

Head Neck. 2019 Feb;41(2):488-494. doi: 10.1002/hed.25434. Epub 2018 Dec 7.

PMID:
30536479
17.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L.

Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009. Epub 2018 Dec 7.

18.

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Downey-Kopyscinski S, Daily EW, Gautier M, Bhatt A, Florea BI, Mitsiades CS, Richardson PG, Driessen C, Overkleeft HS, Kisselev AF.

Blood Adv. 2018 Oct 9;2(19):2443-2451. doi: 10.1182/bloodadvances.2018016360.

19.

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.

Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T.

Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20. No abstract available.

20.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

21.

Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab.

Aeppli S, Driessen C, Graf L, Hitz F.

Hematol Oncol. 2018 Oct;36(4):713-714. doi: 10.1002/hon.2533. Epub 2018 Aug 3. No abstract available.

PMID:
30074631
22.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.

PMID:
30026573
23.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

24.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

PMID:
29251284
25.

Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.

Driessen CML, Groenewoud JMM, de Boer JP, Gelderblom H, van der Graaf WTA, Prins JB, Kaanders JHAM, van Herpen CML.

Support Care Cancer. 2018 Apr;26(4):1233-1242. doi: 10.1007/s00520-017-3946-7. Epub 2017 Dec 11.

26.

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.

Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J.

Nature. 2017 Dec 14;552(7684):194-199. doi: 10.1038/nature25016. Epub 2017 Dec 6.

27.

Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.

Abt D, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, Vodinska M, Slaby O, Schmid HP, Engeler DS, Driessen C, Besse L.

BJU Int. 2018 Apr;121(4):600-609. doi: 10.1111/bju.14083. Epub 2017 Dec 10.

28.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.

Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG 3rd, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M.

Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6.

29.

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.

Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C.

Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69. No abstract available.

30.

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, Bader J, Overkleeft HS, Besse L, Driessen C.

Leukemia. 2018 Feb;32(2):391-401. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5.

31.

Spotlight on pomalidomide: could less be more?

Zander T, Aebi S, Pabst T, Renner C, Driessen C.

Leukemia. 2017 Sep;31(9):1987-1989. doi: 10.1038/leu.2017.156. Epub 2017 May 22. No abstract available.

32.

The effect of early fusion of the spheno-occipital synchondrosis on midface hypoplasia and obstructive sleep apnea in patients with Crouzon syndrome.

Driessen C, Rijken BF, Doerga PN, Dremmen MH, Joosten KF, Mathijssen IM.

J Craniomaxillofac Surg. 2017 Jul;45(7):1069-1073. doi: 10.1016/j.jcms.2017.03.024. Epub 2017 Apr 8.

PMID:
28479031
33.

Update on Treatment of Sagittal Synostosis: What Can We Learn From the 16th Congress of the International Society of Craniofacial Surgery?

Driessen C, Mathijssen I, van Veelen ML.

J Craniofac Surg. 2017 May;28(3):589-590. doi: 10.1097/SCS.0000000000003372. No abstract available.

PMID:
28468130
34.

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.

Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C.

Br J Haematol. 2017 Mar;176(5):770-782. doi: 10.1111/bjh.14481. Epub 2016 Dec 16.

PMID:
27983764
35.

Using a semi-conductor sequencing-based panel for genotyping of HPV-positive and HPV-negative oropharyngeal cancer: a retrospective pilot study.

Ham JC, Tops BBJ, Driessen CML, van Raaij AWM, Slootweg PJ, Melchers WJG, Ligtenberg MJL, van Herpen CML.

Clin Otolaryngol. 2017 Jun;42(3):681-686. doi: 10.1111/coa.12800. Epub 2017 Jan 8.

PMID:
27882657
36.

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.

Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, Bader J, Everts B, den Dulk H, Overkleeft HS, Florea BI, Driessen C.

Leukemia. 2016 Nov;30(11):2198-2207. doi: 10.1038/leu.2016.102. Epub 2016 Apr 27.

37.

Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.

Xin BT, de Bruin G, Huber EM, Besse A, Florea BI, Filippov DV, van der Marel GA, Kisselev AF, van der Stelt M, Driessen C, Groll M, Overkleeft HS.

J Med Chem. 2016 Aug 11;59(15):7177-87. doi: 10.1021/acs.jmedchem.6b00705. Epub 2016 Aug 1.

PMID:
27438186
38.

Multiple myeloma: patient outcomes in real-world practice.

Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M.

Br J Haematol. 2016 Oct;175(2):252-264. doi: 10.1111/bjh.14213. Epub 2016 Jul 13.

39.

Multiple myeloma: practice patterns across Europe.

Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K.

Br J Haematol. 2016 Oct;175(1):66-76. doi: 10.1111/bjh.14193. Epub 2016 Jun 13.

PMID:
27291397
40.

Intestinal-type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment.

Hoeben A, van de Winkel L, Hoebers F, Kross K, Driessen C, Slootweg P, Tjan-Heijnen VC, van Herpen C.

Head Neck. 2016 Oct;38(10):1564-70. doi: 10.1002/hed.24416. Epub 2016 May 25. Review.

PMID:
27224655
41.

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, Miguel JS, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 Jun;76(9):989-990. No abstract available.

PMID:
27206917
42.

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Review. Erratum in: Drugs. 2016 Jun;76(9):989-90.

PMID:
27113582
43.

Development of new Malt1 inhibitors and probes.

Xin BT, Schimmack G, Du Y, Florea BI, van der Marel GA, Driessen C, Krappmann D, Overkleeft HS.

Bioorg Med Chem. 2016 Aug 1;24(15):3312-29. doi: 10.1016/j.bmc.2016.03.035. Epub 2016 Mar 28.

PMID:
27085674
44.

Abnormal transcranial Doppler cerebral blood flow velocity and blood pressure profiles in children with syndromic craniosynostosis and papilledema.

Spruijt B, Tasker RC, Driessen C, Lequin MH, van Veelen ML, Mathijssen IM, Joosten KF.

J Craniomaxillofac Surg. 2016 Apr;44(4):465-70. doi: 10.1016/j.jcms.2016.01.001. Epub 2016 Jan 11.

PMID:
26857754
45.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ.

Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.

46.

Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.

Driessen CM, de Boer JP, Gelderblom H, Rasch CR, de Jong MA, Verbist BM, Melchers WJ, Tesselaar ME, van der Graaf WT, Kaanders JH, van Herpen CM.

Eur J Cancer. 2016 Jan;52:77-84. doi: 10.1016/j.ejca.2015.09.024. Epub 2015 Dec 1.

47.

Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer.

Driessen CM, Uijen MJ, van der Graaf WT, van Opstal CC, Kaanders JH, Nijenhuis T, van Herpen CM.

Head Neck. 2016 Apr;38 Suppl 1:E1575-81. doi: 10.1002/hed.24281. Epub 2015 Nov 28.

PMID:
26614010
48.

A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.

de Bruin G, Xin BT, Kraus M, van der Stelt M, van der Marel GA, Kisselev AF, Driessen C, Florea BI, Overkleeft HS.

Angew Chem Int Ed Engl. 2016 Mar 18;55(13):4199-203. doi: 10.1002/anie.201509092. Epub 2015 Oct 29.

PMID:
26511210
49.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.

J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.

PMID:
26150440
50.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.

Supplemental Content

Loading ...
Support Center